摘要
Abstract
Objective To comprehensively assess the clinical comprehensive value performance of Klorhexadine Dry Suspension compared with similar drugs in the treatment of children's lower respiratory infections,and provide scientific basis for medical policy decisions.Methods Search authoritative databases at home and abroad and incorporate relevant clinical literature.The comprehensive clinical value of clohexine dry suspension in the treatment of lower respiratory tract infections in children was evaluated from six dimensions:safety,efficacy,economy,innovation,suitability and accessibility.Results Whether it is literature reports,data from the National Medical Products Administration(NMPA),or pharmacological and toxicological studies,all indicate that the dry suspension of clohexin has good safety.Meta-analysis shows that clohexin dry suspension has better clinical efficacy in the treatment of lower respiratory tract infections in children,especially in terms of the duration of fever reduction and cough relief compared with similar varieties.Clohexine dry suspension is economically viable in the treatment of lower respiratory tract infections in children.The dry suspension of clohexin has made innovative breakthroughs in both clinical application and industrial development.The technical characteristics of the drug and its application scenarios are all in line with clinical needs.This medicine has a wide sales range,an abundant supply,and imposes a small economic burden on patients regarding its use.Conclusion Clohexin dry suspension has high clinical value in the treatment of lower respiratory tract infections in children.关键词
克洛己新干混悬剂/儿童下呼吸道感染/临床综合评价Key words
Klorhexadine Dry Suspension/Lower respiratory tract infection in children/Clinical comprehensive evaluation分类
医药卫生
